Best Grants for Museums in Guam

The BRAIN Initiative seeks to develop innovative tools and approaches for neuroscience research, focusing on cell-specific and circuit-specific processes within the central nervous system. This initiative encourages projects that enhance our understanding of brain architecture and function through novel technologies for characterizing neural components and advancing methods for recording and modulating neural activity. Applications are invited to address significant challenges and promote transformative breakthroughs in neuroscience.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Clinical Data, Safety and Statistical Centers (CDSSC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance clinical research through comprehensive support. This includes statistical analysis, protocol development, and oversight of safety monitoring in studies related to asthma, autoimmune diseases, and transplantation. By coordinating these efforts, the program seeks to facilitate impactful research outcomes and improve public health outcomes through informed data-driven decisions.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34) aims to support high-risk, multi-center clinical studies by facilitating early peer review and assessment of study designs. This program helps in the development of necessary operational documents and essential elements for conducting hypothesis-driven studies focused on diseases relevant to NIDDK. Applications are due by 5:00 PM local time, and consulting with NIDDK staff is strongly encouraged.

The NIAID aims to enhance our understanding of the interplay between chronic and infectious diseases through innovative precision systems biology research. By utilizing advanced technologies such as multi-omics and artificial intelligence, the initiative focuses on uncovering critical pathways that connect infections to chronic health issues. This multidisciplinary approach leverages longitudinal patient data to inform and improve prevention and treatment strategies, ultimately seeking to provide insights into disease progression and host-pathogen interactions.

The Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enhance research on asthma and related allergic diseases. This initiative fosters multi-center, multidisciplinary research to explore disease mechanisms and treatment responses. By promoting clinical trials and observational studies, the AADCRC seeks to advance understanding and improve interventions for conditions such as asthma and food allergies, ultimately benefiting public health.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing organ transplantation outcomes through the Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) program. This initiative supports multicenter clinical trials and mechanistic studies related to heart, lung, kidney, liver, and intestinal transplants, as well as non-hematopoietic cellular transplantation. By exploring immune mechanisms and innovative therapies, the program aims to enhance the success and efficacy of organ transplantation.

The NIAID aims to enhance infectious disease research by supporting human microphysiologic systems (MPS) development. These in vitro platforms mimic human tissue functions, promoting drug and biological product development while reducing animal use. This initiative aligns with NIH’s commitment to innovative research practices and regulatory acceptance. By focusing on MPS in infectious disease contexts, NIAID seeks to streamline therapeutic advancements and establish robust human tissue models, addressing critical challenges in understanding and treating infections.

The Interdisciplinary Transportation Law and Policy Technology Training Program aims to enhance the skills of policymakers and legal professionals in adapting to rapid advancements in transportation technology, including AI and automated vehicles. This initiative will allocate $600,000 to develop a comprehensive training curriculum, including a week-long course for support staff and a semester-long program for law students. The project will be executed over a 24-month period, targeting University Transportation Centers and their consortia.

The NIDA Mentored Clinical Scientist Development Program Award aims to foster research independence in clinician scientists by providing intensive supervised research training and career development in the field of substance use and substance use disorder. Applications are due by 5:00 PM local time of the applicant organization, ensuring timely submission for this essential funding opportunity.

The NIH StrokeNet initiative invites applications for multi-site exploratory and confirmatory clinical trials targeting interventions for stroke prevention, treatment, and recovery. This includes biomarker validation studies and ancillary studies to enhance active research. Successful applicants will collaborate within the NIH StrokeNet framework, with support from the National Coordinating Center and Data Management Center to ensure efficient study implementation and robust statistical analysis. Key deadlines for application submissions span from March 2024 to November 2026.

The Feasibility Clinical Trials of Mind and Body Interventions (R34) program seeks to support trials focused on complementary health approaches for conditions identified as high-priority by NCCIH. This funding opportunity aims to gather essential data necessary for planning future clinical efficacy studies. Applicants must demonstrate the feasibility of interventions and their potential impact on public health. Contacting NCCIH scientific contacts before submission is encouraged, and a Plan for Enhancing Diverse Perspectives is required.

This funding opportunity invites applications for investigator-initiated clinical trials focused on complementary and integrative health interventions delivered remotely or via mobile health technologies. The trials must be fully powered, with no in-person contact, and require justification for this approach. Preliminary data on feasibility and safety must be provided, alongside evidence of clinical benefit. A Plan for Enhancing Diverse Perspectives is mandatory for submission. Key deadlines range from February 2024 to June 2026.

The NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01) invites applications for clinical trials focusing on complementary and integrative health approaches. This funding opportunity emphasizes the importance of multisite feasibility trials to gather essential data for planning future efficacy studies. Deadlines for standard and AIDS-related applications range from February 2024 to November 2026, underscoring the urgency for innovative research in high-priority areas.

The Placement and Coordination Program, administered by the Office of Refugee Resettlement, invites eligible organizations to enhance refugee resettlement services. By diversifying service providers, the program aims to strengthen the national resettlement framework. Key responsibilities include managing the Program of Initial Resettlement and Intensive Case Management for vulnerable refugees, ensuring comprehensive support from arrival through initial resettlement, and addressing barriers to self-sufficiency.

The NIDDK is expanding its Gastroparesis Consortium into the Disorders of Gastrointestinal Interoception Consortium (DGIC) to explore various GI disorders linked to interoceptive processing. This initiative aims to include multiple Clinical Research Centers and a Scientific Data Research Center, focusing on multidisciplinary approaches to uncover mechanisms connecting GI function to symptoms. The effort seeks to identify biomarkers and novel therapeutic targets for future clinical trials, enhancing understanding and treatment of complex gastrointestinal conditions.

The FY26 Neurofibromatosis Research Program's Synergistic Idea Award supports innovative research on neurofibromatosis (NF) through collaborative efforts of two or three Principal Investigators (PIs). By leveraging their unique perspectives, these PIs will tackle significant questions in NF research. Applicants must provide relevant preliminary or published data to support their proposals, ensuring a strong foundation for impactful research outcomes.

The DoW Neurofibromatosis Investigator-Initiated Research Award addresses critical needs in neurofibromatosis research, aiming to enhance patient care through innovative projects. It supports various research phases, excluding clinical trials, and encourages collaboration between scientists and clinicians. The funding mechanism includes two levels based on participation in optional features, such as the Open Science Initiative and collaboration with qualified partners, promoting data sharing and collaborative research efforts.

The FY26 Neurofibromatosis Research Academy – Scholar Award supports early-career independent investigators focusing on neurofibromatosis research. Scholars are required to be within 10 years of their terminal degree and must designate a Career Guide for mentorship, fostering collaboration. This initiative aims to advance impactful research and develop skilled researchers in a supportive environment, addressing critical areas of emphasis in neurofibromatosis research.

The Peggy Barber Tribute Grant, offered by the American Library Association, supports libraries facing budget constraints by providing $2,500 to three selected libraries. The 2025-2026 cycle focuses on programming that strengthens community ties through libraries as third spaces, promoting gatherings and connections among individuals. Eligible proposals may include intergenerational gardening programs, play-based activities for adults, or visual arts performances. Applicants must have ALA or ARSL membership and demonstrate how their program will foster community engagement.

The DoW Rare Cancers Idea Development Award promotes innovative research ideas for rare cancers, encouraging applicants to provide preliminary data and exploratory aims. This funding opportunity, offered by the US DOD: U.S. Army Medical Command, seeks projects with the potential for high-impact findings that can significantly benefit the patient community. It aims to foster new avenues of investigation and support discovery-driven research in the field of rare cancers.

The FY26 Duchenne Muscular Dystrophy Research Program's Idea Development Award promotes innovative, high-risk research aimed at advancing treatment for Duchenne muscular dystrophy (DMD). It encourages projects with a strong scientific basis and feasibility, focusing on therapies that work across all ages, including infants and nonambulatory patients. Eligible applicants include experienced and transitioning investigators, fostering diverse expertise to enhance DMD research and improve patient outcomes.

The EPSCoR Research Infrastructure Improvement (RII): EPSCoR Research Fellows program, funded by the National Science Foundation (NSF), aims to enhance research capacity and workforce development in STEM. This initiative fosters collaborations between underrepresented researchers and leading institutions, providing essential resources and support. With two tracks available—one focusing on NSF and the other on NASA—this program uniquely positions Fellows to leverage transformative research experiences and contribute to sustainable advancements in their respective fields.

The Limited Competition NOFO aims to provide ongoing support for specific pathogen-free (SPF) macaque colonies that facilitate vital HIV/AIDS research. Only recipients funded under previous ORIP-supported SPF colony announcements are eligible to apply. These breeding colonies are crucial for maintaining SPF macaques, which are free from certain viruses that could jeopardize research outcomes. The project emphasizes the genetic characterization of macaques to enhance understanding of immune responses related to HIV and SIV.

The FY26 Duchenne Muscular Dystrophy Research Program's Clinical/Translational Research Award supports pivotal research aimed at translating innovative therapeutic strategies into clinical applications for Duchenne muscular dystrophy (DMD). Two funding levels cater to diverse project complexities, along with a Partnering PI Option promoting collaboration between early-career and established investigators. This initiative emphasizes the integration of preliminary data and encourages pilot trials to advance DMD therapies effectively.